Clinical trial Recruiting at 1 site Observational Ages 18 and up

Heart Rate Variability as a Marker to Guide High-Flow Nasal Cannula Therapy

Official title: Heart Rate Variability as a Marker for Titrating High Flow Nasal Cannula Therapy in Patients With Respiratory Failure

Run by University Health Network, Toronto · NCT07518862 · Data updated 2026-11-12

We’re testing whether heart rate variability can help decide the right flow rate for high-flow nasal cannula in adults with respiratory failure.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity Health Network, Toronto
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedMay 26, 2026
Main results expectedNovember 2026
Study endsDecember 2026
Registry record updatedJune 18, 2026
Trial IDNCT07518862 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 years receiving high-flow nasal cannula therapy for respiratory failure at Toronto General Hospital.

Probably not a fit

Patients with certain arrhythmias or devices or those not able to undergo ECG/EIT measurements may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study explores whether heart rate variability (HRV) can guide titration of high-flow nasal cannula therapy in adults with respiratory failure. Researchers will monitor HRV (and related ECG/EIT data) to see if autonomic nervous system changes align with the patient’s respiratory needs. The goal is to identify if HRV signals can help avoid under- or over-support with HFNC, potentially reducing ICU stays and costs. The study design is observational, focusing on relationships between HRV metrics and HFNC settings rather than testing a specific intervention. Eligible participants are adults receiving HFNC at Toronto General Hospital under non-experimental conditions.

Why it matters

Potential benefit: If successful, HRV-guided titration could improve patient comfort and outcomes while reducing ICU time and resource use.

How similar studies have gone: Prior work shows HFNC can help with respiratory failure, but HRV-guided titration is a novel approach that requires further evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18
* Currently receiving High-Flow Nasal Cannula Therapy

Exclusion Criteria:

* FiO2 ≥ 90%
* Pacemaker rhythm or presence of atrial fibrillation
* Post-cardiac surgery patients
* Contra-indications to electrical impedance tomography (EIT) and/or electrocardiogram (ECG) (active implantable medical device, burns, thoracic wounds limiting electrode placement)
* Non-English-speaking

Where it's running

  • Toronto General Hospital
    Toronto, Ontario, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.